Methods for treating pulmonary hypertension
AssigneeChiesi Farmaceutici S.p.A.
InventorsDavid Kylhammar, Goran Radegran
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for treating or preventing pulmonary hypertension, reducing mortality in a subject experiencing pulmonary hypertension, or inhibiting ADP-mediated vasoconstriction of pulmonary arteries in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a reversible P2Y12 receptor antagonist. Also provided are related medicaments, pharmaceutical compositions, and methods for preparing the medicaments.
Claims15
A method of treating pulmonary hypertension in a subject in need thereof, consisting essentially of administering to the subject a pharmaceutical composition consisting essentially of (a) an active ingredient, wherein the active ingredient is cangrelor;
- and (b) optionally one or more pharmaceutically acceptable carriers, a second agent as diluents, a third agent as excipients, or a combination thereof;
- and performing a measurement to determine the decrease of mean pulmonary artery pressure after administration of cangrelor.
A method of reducing mortality in a subject experiencing pulmonary hypertension, consisting essentially of administering to the subject a composition consisting essentially of (a) an active ingredient, wherein the active ingredient cangrelor;
- and (b) optionally one or more pharmaceutically acceptable carriers, a second agent as diluents, a third agent as excipients, or a combination thereof;
- and performing a measurement to determine the decrease of mean pulmonary artery pressure after administration of cangrelor.
A method of inhibiting ADP-mediated vasoconstriction of pulmonary arteries in a subject in need thereof, consisting essentially of administering to the subject a composition consisting essentially of (a) an active ingredient, wherein the active ingredient is-cangrelor;
- and (b) optionally one or more pharmaceutically acceptable carriers, a second agent as diluents, a third agent as excipients, or a combination thereof;
- and performing a measurement to determine the decrease of mean pulmonary artery pressure after administration of cangrelor.
Dependencies are inferred from the claim text.